January 28, 2014
1 min read

Bio-Tissue announces 35% compound growth

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Bio-Tissue Inc. reported 33% unit growth and a 7-year compounded annual growth rate of 35%. As stated in a press release, nearly 200,000 product units have been shipped since 2006, resulting in more than 150,000 successful human transplantations to manage ocular surface diseases and conditions.

Chairman and Chief Scientific Officer Scheffer Tseng, MD, PhD said in the release, “This accomplishment serves as an endorsement in Bio-Tissue’s technology platforms, which go a long way in the treatment and management of ocular surface diseases. We are confident that the products Bio-Tissue has developed through ongoing evidence-based research will become the new paradigm for eye care professionals seeking to improve clinical outcomes and enhance patients’ quality of life.”

Bio-Tissue’s product lines include AmnioGraft, AmnioGuard, Prokera and Cliradex.